Group 1 - The core viewpoint of the news is that Yiming Biotech has made significant progress in the development of innovative drugs for autoimmune diseases, specifically with the acceptance of the clinical trial application for its dual-target antibody IMM0306S by the National Medical Products Administration (NMPA) [1] - IMM0306S is a subcutaneous formulation developed based on Yiming Biotech's core product IMM0306, which is the world's first clinical-stage dual-target specific molecule targeting CD47 and CD20, developed using the "mAb-Trap" technology platform [1] - The stock price of Yiming Biotech increased by nearly 4%, with a current trading price of 6.23 HKD and a trading volume of 3.12 million HKD [1] Group 2 - At the 67th American Society of Hematology (ASH) annual meeting, Yiming Biotech presented data from a Phase I/II clinical study of IMM0306 combined with lenalidomide for the treatment of relapsed/refractory CD20-positive follicular lymphoma, showing an objective response rate (ORR) of 91.2% and a complete response (CR) rate of 67.6% in patients who had failed at least one line of anti-CD20 monoclonal antibody treatment [2] - The safety profile of the combination therapy was reported to be manageable, with no risk of cytokine release syndrome, providing a promising new immunotherapy strategy for this currently incurable disease with limited treatment options after relapse [2]
宜明昂科-B涨近4% 自研阿沐瑞芙普α皮下制剂IMM0306S临床研究申请获受理